Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Repair With or Without Leuprorelin for Cesarean Section Scar Defect
NCT05206682Recruiting
- Sponsor
- Xinhua Hospital
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of leuprolide in cesarean scar defect (CSD) and adenomyosis (2 arms), sponsored by Xinhua Hospital. Primary endpoints: Thickness of the remaining muscular layer at 12 weeks and Duration of menstruation at 12 weeks. Started May 2023; status: recruiting.
02
Drugs
leuprolide
03
Conditions
cesarean scar defect (CSD)adenomyosis
Beyond the preview
Go deeper on NCT05206682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206682.